ArticleTurkish journal of medical sciences2025
Impact of pulmonary metastasectomy timing and nodule characteristics on survival outcomes in patients with pediatric sarcoma.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Pulmonary metastasectomy (PM) is a crucial intervention for patients with metastatic sarcomas, particularly among pediatric populations. The timing of PM and its impact on survival outcomes remain a subject of debate in the literature. This study aims to evaluate the impact of PM on survival outcomes. Materials and methods: This retrospective study included pediatric patients diagnosed with sarcomas who underwent pulmonary metastasectomy. Demographic and clinical characteristics, including age, sex, primary malignancy type, metastasis presence at diagnosis, chemotherapy response, and PM details (e.g., number and laterality of metastatic nodules, time from metastasis detection to surgery) were analyzed. Survival data were assessed using Kaplan-Meier curves and Cox regression analysis, and statistical significance was determined using log-rank tests. Results: A total of 29 patients (51.7% male, 48.3% female) were included, with 55.2% presenting with metastasis at diagnosis. Overall, 47 surgical procedures were performed. The 5-year survival rate following PM was significantly higher for patients who underwent surgery within 30 days of metastasis detection (75.26%) compared to those who had surgery later (35.88%, p = 0.031). In univariate analysis, both 5-year survival after nodule detection and 5-year survival after metastasectomy were better in patients who underwent PM within the first 30 days (p = 0.022 and p = 0.039, respectively). Additionally, the number of metastatic nodules (< 10 versus ≥ 10) and the number of nodules per operation (< 3 versus ≥ 3) were significant factors influencing survival. Patients with fewer metastatic nodules exhibited better 5-year survival rates. The survival outcomes were comparable across different sarcoma subtypes, including osteosarcoma, Ewing sarcoma, and synovial sarcoma. Conclusion: Our study suggests that early pulmonary metastasectomy, performed within 30 days of metastasis detection, improves 5-year survival in pediatric sarcoma patients. The number of metastatic nodules and the timing of surgery are critical factors in determining survival outcomes. These findings highlight the importance of timely surgical intervention and careful evaluation of metastasis extent in optimizing patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.